CXCL12 and age-related macular degeneration: Correspondingly, treatment with AMD3100 impaired tube formation in strongly vasculogenic clones, including CL22 (control vs. AMD, 18.4±2.1 vs. 10.8±1.2, n = 10, p<0.01) and CL42A1 (16.1±1.8 vs. 8.20±0.10, n = 10, p<0.01) in a manner that was reversed by exogenous SDF-1 (CL22: AMD vs. AMD+SDF-1, 10.8±1.2 vs. 22.8±1.5, n = 10, p<0.001; CL42A1: 8.20±0.10 vs. 14.2±1.8, n = 10, p<0.05) (Figure 6C).